Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Irving Investors

Investor type Venture Capital
Founders Jeremy Abelson


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 40
Average round size
The average size of a deal this fund participated in
Portfolio companies 34
Rounds per year 3.08
Lead investments 2
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 11
Key employees 1
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Life Science
  • E-Commerce

In 2009 was created Irving Investors, which is appeared as Corporate Investor. The venture was found in North America in United States. The main office of represented Corporate Investor is situated in the New York.

The current fund was established by Jeremy Abelson.

Speaking about the real fund results, this Corporate Investor is 3 percentage points less often commits exit comparing to other organizations. Deals in the range of more than 100 millions dollars are the general things for fund. This Irving Investors works on 4 percentage points more the average amount of lead investments comparing to the other organizations. The fund is generally included in less than 2 deals every year. The typical startup value when the investment from Irving Investors is 500 millions - 1 billion dollars. The higher amount of exits for fund were in 2018. The important activity for fund was in 2019.

The fund has exact preference in a number of founders of portfolio startups. When startup sums 1 or 3 of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Manufacturing, Health Care. Among the most popular portfolio startups of the fund, we may highlight Lyft, Anaplan, PAX Labs. Besides, a startup needs to be aged 6-10 years to get the investment from the fund.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Irving Investors, startups are often financed by The Column Group, Rainfall Ventures, Norwest Venture Partners. The meaningful sponsors for the fund in investment in the same round are Goldman Sachs, blisce/, Tresalia Capital. In the next rounds fund is usually obtained by Sequoia Capital, Khosla Ventures, K9 Ventures.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Irving Investors:
Typical Co-investors
Irving Investors is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Irving Investors:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AlphaLab Gear Pennsylvania, Pittsburgh, United States
Arctos Capital California, San Francisco, United States
Chengdu Dingxiang Chuangtou Chengdu, China, Sichuan
Ellis Accelerator New York, New York, United States
Eos Capital Khomas, Namibia, Windhoek
FullCycle California, Los Angeles, United States
Hangzhou Kang Sheng Health Management -
Hanwha Asset Management Seoul, Seoul-t'ukpyolsi, South Korea
Harbor Spring Capital New York, New York, United States
Harvest Capital Credit Corporation New York, New York, United States
Health for Life Capital fund -
Partners Financial Services Czech Republic, Prague, Prague
Powerscourt Capital Partners County Dublin, Dublin, Ireland
Rongtong Capital Management China, Guangdong, Shenzhen
Russian Foundation for Technological Development -
SARORAS Private Capital New York, New York, United States
Shelter Capital Partners California, Los Angeles, United States
Startupbootcamp Smart City & IoT Amsterdam Amsterdam, Noord-Holland, The Netherlands
Warson Capital Partners Missouri, Missouri City, United States
Xinganxian Media Investment China, Hangzhou, Zhejiang

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Leap Services

E-Commerce Platforms
Retail Technology
$50M27 Jan 2022 Chicago, Illinois, United States


Artificial Intelligence
Machine Learning
$175M25 Jan 2022 California, United States


Developer APIs
Enterprise Software
Human Resources
Information Services
Legal Tech
18 Jan 2022 San Francisco, California, United States

Arctic Wolf

Cyber Security
Information Technology
Network Security
06 Jan 2022 Minnesota, United States

DNA Script

Health Care
Life Science
$200M04 Jan 2022 France, Ile-de-France, France


01 Dec 2021 New York, New York, United States

Shoreline Biosciences

Life Science
$140M02 Nov 2021 San Diego, California, United States


Life Science
$201M02 Aug 2021 South San Francisco, California, United States


Chemical Engineering
Renewable Energy
$118M27 Jul 2021 San Diego, California, United States
InterVenn Biosciences Raises $201 Million for AI-driven Glycoproteomic Platform, Liquid-Biopsy development

– InterVenn Biosciences announced the completion of a $201m Series C financing.
– The funding round was led by new investors SoftBank Group, Heritage Provider Network, Irving Investors, Highside Capital Management, and backed by existing investors Amplify Partners, Anzu Partners, Genoa Ventures and True Ventures.
– The proceeds from the financing will be used to accelerate development and commercialization of Dawn, the company’s liquid biopsy assay for immune checkpoint inhibitor response prediction, and to expand the network of partners on the company’s AI-driven glycoproteomics platform.
– To date, the InterVenn glycoproteomics platform has been used to develop 16 clinical use cases across oncology and other indications. Dawn is currently under development and is planned to be commercialized in 2022.

Cybereason Receives $275M in Crossover Financing

– Cybereason from Boston, MA provides a future-ready attack protection platform that unifies security from the endpoint to the enterprise to everywhere the battle moves.
– The company raised $275m in crossover financing.
– The round was led by Liberty Strategic Capital with participation from Irving Investors, certain funds advised by Neuberger Berman Investment Advisers LLC, and Softbank Vision Fund 2.
– The company intends to use the funds to continue to accelerate the growth driven by demand for its AI-powered platform.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Irving Investors?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: